R&D Trends

Amgen, Novartis join Atlas Venture Fund IX as corporate strategic partners

Friday, May 17, 2013 12:25 PM

Atlas Venture, an early-stage venture capital firm that invests in technology and life sciences companies, has entered into Corporate Strategic Partnership (CSP) agreements with both Amgen, through its venture capital fund, Amgen Ventures, and Novartis. The CSP agreements are in conjunction with the closing of Atlas IX in which Amgen Ventures and Novartis are new limited partners. 

More... »

Sorrento, Igdrasol acquire E.U. distribution rights to Cynviloq from Samyang

Wednesday, May 15, 2013 12:46 PM

Sorrento Therapeutics, a development-stage biopharmaceutical company, and Igdrasol, a developer of personalized paclitaxel, have acquired exclusive distribution rights from Samyang Biopharmaceuticals, a South Korean corporation, to Cynviloq (marketed as Genexol-PMR in South Korea) in the 27 countries of E.U.

More... »

Cobra Biologics, Vaccibody to manufacture DNA vaccine

Wednesday, May 15, 2013 12:21 PM

Cobra Biologics, an international clinical and commercial manufacturer of biologics and pharmaceuticals, and Vaccibody, a biotechnology company developing the next generation of vaccines against cancer and chronic infections, have signed an agreement to manufacture Vaccibody’s lead DNA vaccine candidate against HPV-induced malignancies, such as precancerous lesions found in cervical cancer.

More... »

Adaptive, BMS ink biomarker discovery collaboration agreement

Wednesday, May 15, 2013 11:57 AM

Adaptive Biotechnologies, a Seattle-based developer of next generation sequencing assays, has entered into a collaboration agreement with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology.

More... »

Trevena, Forest Labs to develop TRV027 for acute heart failure

Thursday, May 9, 2013 11:16 AM

Trevena, a clinical stage pharmaceutical company focused on G-protein coupled receptor (GPCR) biased ligands, and Forest Laboratories, a global pharmaceutical company, have entered into a collaborative licensing option agreement for the development of TRV027, an AT1R biased-ligand that recently completed phase IIa clinical trials. Trevena expects to commence a 500-patient multi-center phase IIb clinical trial in acute decompensated heart failure (ADHF) by year end.

More... »

MJFF launches new funding opportunities for Parkinson's research

Thursday, May 9, 2013 10:01 AM

The Michael J. Fox Foundation (MJFF) launched three new funding programs focused on driving research toward transformative treatments and a cure for Parkinson's disease.

More... »

Aesica, University of Nottingham to develop novel amide chemical synthesis technique

Wednesday, May 8, 2013 11:36 AM

Aesica, a global contract manufacturing organization, has formed a partnership with the University of Nottingham for the commercial development of alternative methods in amide bond synthesis.

More... »

Recipharm, Synthonics to promote novel drug delivery technology

Wednesday, May 8, 2013 09:40 AM

Recipharm Pharmaceutical, a Swedish contract development and manufacturing organization (CDMO), and Synthonics, a specialty pharmaceutical company based in Blacksburg, Va., have formed a Joint Promotion Agreement.

More... »

Concert Pharmaceuticals, Celgene to develop deuterium-modified compounds

Tuesday, May 7, 2013 08:00 AM

Concert Pharmaceuticals, a clinical stage biotechnology company, has entered into a strategic collaboration with Celgene, a Summit, N.J.-based integrated global biopharmaceutical company, directed towards deuterium-modified compounds targeting cancer and inflammation. The collaboration will initially focus on one program, but has the potential to encompass multiple targets.

More... »

Ambrx, BMS collaborate on next-gen antibody drug conjugates

Monday, May 6, 2013 10:09 AM

Ambrx, a clinical stage biopharmaceutical company, entered into a collaboration agreement with Bristol-Myers Squibb for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology.

More... »